NVCT Latest Press Releases

-- November 4, 2026 --

Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- November 2, 2026 --

Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 Globe Newswire 5:00 PM

-- October 26, 2026 --

Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas Globe Newswire 8:30 AM

-- October 9, 2026 --

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 Globe Newswire 8:00 AM

-- September 24, 2026 --

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma Globe Newswire 8:00 AM

-- September 3, 2026 --

Nuvectis Pharma To Participate in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 4, 2026 --

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights Globe Newswire 8:00 AM

-- July 23, 2026 --

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Globe Newswire 9:00 AM

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Globe Newswire 7:30 AM

-- June 29, 2026 --

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock Globe Newswire 10:30 PM

Nuvectis Pharma Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

-- June 22, 2026 --

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes